Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
2.

BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.

Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A.

Br J Cancer. 2007 May 21;96(10):1549-53. Epub 2007 Apr 24.

3.

Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.

González-Cámpora R, Galera-Ruiz D, Armas-Padrón JR, Otal-Salaverri C, Galera-Davidson H.

Diagn Cytopathol. 1998 Jul 1;19(1):4-8.

PMID:
9664176
4.

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE.

J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404.

PMID:
14602780
5.

Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma.

Song YS, Won JK, Yoo SK, Jung KC, Kim MJ, Kim SJ, Cho SW, Lee KE, Yi KH, Seo JS, Park YJ.

Thyroid. 2018 Nov;28(11):1468-1478. doi: 10.1089/thy.2018.0198. Epub 2018 Oct 16.

PMID:
30226444
6.

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.

Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH.

Mod Pathol. 2004 Nov;17(11):1359-63.

7.

Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.

Jung CK, Kim Y, Jeon S, Jo K, Lee S, Bae JS.

Hum Pathol. 2018 Nov;81:9-17. doi: 10.1016/j.humpath.2018.04.018. Epub 2018 May 1.

8.

The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93.

PMID:
16268813
10.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86. Epub 2010 May 14.

12.

Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.

Xu B, Tuttle RM, Sabra MM, Ganly I, Ghossein R.

Thyroid. 2017 May;27(5):632-640. doi: 10.1089/thy.2016.0582. Epub 2017 Feb 1.

13.

Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.

Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.

Cancer Cytopathol. 2015 Oct;123(10):593-602. doi: 10.1002/cncy.21586. Epub 2015 Jul 31.

14.

Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.

Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK, Yang JH.

Thyroid. 2016 Jul;26(7):901-10. doi: 10.1089/thy.2015.0488. Epub 2016 Jun 6.

PMID:
27184112
15.

Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.

Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD.

Mol Cancer Ther. 2018 Jul;17(7):1575-1584. doi: 10.1158/1535-7163.MCT-17-0871. Epub 2018 Apr 25.

PMID:
29695638
16.
17.

Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures.

Cracolici V, Mujacic I, Kadri S, Alikhan M, Niu N, Segal JP, Rosen LE, Sarne DH, Morgan A, Desouky S, Cipriani NA.

Endocr Pathol. 2018 Mar;29(1):9-14. doi: 10.1007/s12022-017-9491-6.

PMID:
28710706
18.

BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.

Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG.

Endocr Pathol. 2012 Jun;23(2):83-93. doi: 10.1007/s12022-011-9184-5.

PMID:
22105775
19.

Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.

Johnson DN, Furtado LV, Long BC, Zhen CJ, Wurst M, Mujacic I, Kadri S, Segal JP, Antic T, Cipriani NA.

Arch Pathol Lab Med. 2018 Jul;142(7):838-850. doi: 10.5858/arpa.2017-0118-OA. Epub 2018 Mar 27.

PMID:
29582677
20.

Thyroid carcinoma, version 2.2014.

Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80; quiz 1680.

PMID:
25505208

Supplemental Content

Support Center